ecteinascidin 743 has been researched along with Hodgkin Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aldinucci, D; Borghese, C; Casagrande, N | 2 |
| Aldinucci, D; Borghese, C; Casagrande, N; Favero, A; Vicenzetto, C | 1 |
1 review(s) available for ecteinascidin 743 and Hodgkin Disease
| Article | Year |
|---|---|
Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.
Topics: Antibodies, Monoclonal, Humanized; Chemokines; Cytokines; Hodgkin Disease; Immunosuppressive Agents; Killer Cells, Natural; Maraviroc; Nivolumab; Prognosis; Receptors, CCR5; Reed-Sternberg Cells; T-Lymphocytes; Trabectedin; Tryptophan; Tumor Escape; Tumor Microenvironment; Zoledronic Acid | 2019 |
2 other study(ies) available for ecteinascidin 743 and Hodgkin Disease
| Article | Year |
|---|---|
In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability.
Topics: CCR5 Receptor Antagonists; DNA Damage; HIV Infections; Hodgkin Disease; Humans; Maraviroc; Receptors, CCR5; Trabectedin | 2022 |
Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Immunosuppressive Agents; Mice; Monocytes; Neoplasm Proteins; Trabectedin; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |